These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11422074)

  • 1. Non-pigmenting fixed drug eruption: a new case due to eperisone hydrochloride.
    Choonhakarn C
    Br J Dermatol; 2001 Jun; 144(6):1288-9. PubMed ID: 11422074
    [No Abstract]   [Full Text] [Related]  

  • 2. [A case of eperisone hydrochloride (myonal)--induced drug eruption leading to erythema and angioedema].
    Ueno T; Kawana S
    Arerugi; 2007 Jul; 56(7):709-13. PubMed ID: 17671415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of eperisone hydrochloride-induced acute generalized exanthematous pustulosis.
    Yamamoto Y; Kadota M; Nishimura Y
    J Dermatol; 2004 Sep; 31(9):769-70. PubMed ID: 15628328
    [No Abstract]   [Full Text] [Related]  

  • 4. Non-pigmented fixed drug eruption induced by eprazinone hydrochloride.
    Tanabe K; Tsuboi H; Maejima H; Arai S; Katsuoka K
    Dermatol Online J; 2005 Dec; 11(3):25. PubMed ID: 16409921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muscle Strength Decline Caused by Eperisone Hydrochloride: A Case Report.
    Zhu J; Xiao J; Hu J; Shen J; Chen B; Zhao C
    Clin Ther; 2024 Jan; 46(1):74-78. PubMed ID: 37914584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fixed drug eruption due to afloqualone: the first reported case.
    Demitsu T; Tomita Y
    J Dermatol; 1998 Feb; 25(2):136. PubMed ID: 9563286
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of eperisone hydrochloride in the treatment of acute musculoskeletal spasm associated with low back pain: a randomized, double-blind, placebo-controlled trial.
    Chandanwale AS; Chopra A; Goregaonkar A; Medhi B; Shah V; Gaikwad S; Langade DG; Maroli S; Mehta SC; Naikwadi A; Pawar DR
    J Postgrad Med; 2011; 57(4):278-85. PubMed ID: 22120855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum concentration of eperisone hydrochloride correlates with QT interval.
    Yamagiwa T; Morita S; Amino M; Miura N; Saito T; Inokuchi S
    Am J Emerg Med; 2014 Jan; 32(1):75-7. PubMed ID: 24135462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open experience with a new myorelaxant agent for low back pain.
    Sartini S; Guerra L
    Adv Ther; 2008 Oct; 25(10):1010-8. PubMed ID: 18836866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photoleukomelanodermatitis (Kobori) induced by afloqualone.
    Ishikawa T; Kamide R; Niimura M
    J Dermatol; 1994 Jun; 21(6):430-3. PubMed ID: 8064007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonpigmenting fixed drug eruption: a new case due to betahistine.
    Dereure O; Guilhou JJ
    Dermatology; 1996; 193(3):248-50. PubMed ID: 8944350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience with eperisone in the treatment of acute low back pain.
    Beltrame A; Grangiè S; Guerra L
    Minerva Med; 2008 Aug; 99(4):347-52. PubMed ID: 18663343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fixed eruption due to quinine in tonic water: a case report with high-performance liquid chromatography and ultraviolet A analyses.
    Ohira A; Yamaguchi S; Miyagi T; Yamamoto Y; Yamada S; Shiohira H; Hagiwara K; Uno T; Uezato H; Takahashi K
    J Dermatol; 2013 Aug; 40(8):629-31. PubMed ID: 23724855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics of eperisone-induced immediate-type hypersensitivity.
    Shin B; Yoon SY; Lee JH; Won HK; An J; Kang Y; Song WJ; Kim TB; Cho YS; Moon HB; Kwon HS
    Asian Pac J Allergy Immunol; 2020 Dec; 38(4):279-285. PubMed ID: 30903996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of eperisone in patients with low back pain: a double blind randomized study.
    Cabitza P; Randelli P
    Eur Rev Med Pharmacol Sci; 2008; 12(4):229-35. PubMed ID: 18727454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of eperisone in patients with spastic palsy: a cross-over, placebo-controlled dose-ranging trial.
    Bresolin N; Zucca C; Pecori A
    Eur Rev Med Pharmacol Sci; 2009; 13(5):365-70. PubMed ID: 19961042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral muscle relaxant may induce immediate allergic reactions.
    Hur GY; Hwang EK; Moon JY; Ye YM; Shim JJ; Park HS; Kang KH
    Yonsei Med J; 2012 Jul; 53(4):863-5. PubMed ID: 22665359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-pigmenting fixed drug eruption induced by sorafenib.
    Tanabe K; Amoh Y; Mii S; Eto H; Iwamura M; Katsuoka K
    Acta Derm Venereol; 2010 May; 90(3):307. PubMed ID: 20526556
    [No Abstract]   [Full Text] [Related]  

  • 19. [Case of an allergic reaftion to mydocalm].
    Aleksandrov IuS; Danilov LN
    Klin Med (Mosk); 1974 Apr; 52(4):142. PubMed ID: 4459560
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetic interactions between eperisone hydrochloride and aceclofenac: a randomized, open-label, crossover study of healthy Korean men.
    Kim MJ; Lim HS; Noh YH; Kim YH; Choi HY; Park KM; Kim SE; Bae KS
    Clin Ther; 2013 Oct; 35(10):1528-35. PubMed ID: 24050970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.